IP Library Granted Patent US 8,642,085
Granted Patent B2
US 8,642,085 · App. 12/641,171 · Granted Feb 4, 2014

Systems, methods, and compositions for prevention of tissue adhesion

Inventors: Charles Vaughn Cassingham (Newport Beach, CA); William Jerome Mezger (Coto de Caza, CA)
Assignee: Neomend, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,642,085
App. No.
12/641,171
Granted
Feb 4, 2014
Kind
B2
Abstract

A blended electrophilic material with a first component having a functionality of at least three and a second component having a functionality of two is mixed with a nucleophilic material. The blended electrophilic material cross-links with the nucleophilic material to form a non-liquid, three dimensional structure which can applied, e.g., as an adhesion barrier.

Claims (13)

1. A method comprising:

providing a blended electrophilic material comprising a first poly(ethylene glycol) PEG component having a functionality of at least three and a second PEG component having a functionality of two;

providing a nucleophilic material comprising a recombinantly produced protein, which upon mixing with the blended electrophilic material, cross-links with the blended electrophilic material to form a non-liquid, three dimensional structure; and

mixing the blended electrophilic material and the nucleophilic material to form the non-liquid, three dimensional structure.

2. A method according to claim 1 wherein the non-liquid, three dimensional structure forms upon tissue.

3. A method according to claim 2 wherein the non-liquid, three dimensional structure comprises an adhesion barrier.

4. A method according to claim 1 wherein the first PEG component comprises between 10% to 90% w/w of the blended electrophilic material.

5. A method according to claim 1 wherein the first PEG component has a functionality of four.

6. A method according to claim 1 wherein the first PEG component comprises about 50% w/w of the blended electrophilic material.

7. A method according to claim 1 further including a buffer material.

8. A method according to claim 1 wherein the protein comprises recombinant serum albumin.

9. A method according to claim 8 wherein the recombinant serum albumin is at a concentration of 25% or less.

10. A method according to claim 8 wherein the recombinant serum albumin is at a concentration of about 15%.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2010
From: CASSINGHAM, CHARLES VAUGHN; MEZGER, WILLIAM JEROME
To: NEOMEND, INC.
Reel/Frame 023744/0421 →
Continuity (6)
Division 11716266 · Mar 9, 2007
Continuation In Part 10141510 · May 8, 2002
Continuation In Part 09780843 · Feb 9, 2001
Continuation In Part 09283535 · Apr 1, 1999
Continuation In Part 09188083 · Nov 6, 1998
Related Publication 20100099852A1 · Apr 22, 2010